The naturally identified minor cannabinoids

Full name. Cannabinol.

Origin. Oxidation product mainly associated with the transformation of THC over time.

CBN is generally present in small amounts in fresh plant material and increases in some aged or oxidised products. Its activity on CB1 is weaker than that of delta-9-THC. Human data remain too limited to make it synonymous with a 'sleep cannabinoid' or to promise a predictable sedative effect.

In a recipe, CBN can be presented as a minor cannabinoid with a distinct profile, provided reported uses or preclinical results are not turned into a claim.

Full name. Cannabidivarinic acid and cannabidivarin.

Origin. Propyl homologues of CBDA and CBD.

CBDVA is the acid form that can decarboxylate into CBDV. These molecules have been identified in certain varieties and are not considered intoxicating. CBDV has been the subject of preclinical work and early clinical evaluations, notably in neurology, without any routine use or general benefit being considered established.

Full name. Tetrahydrocannabivarinic acid and tetrahydrocannabivarin.

Origin. Propyl homologues of THCA and THC.

THCVA can decarboxylate into THCV. THCV's pharmacology depends heavily on dose and the model studied: its interaction with CB1 amounts neither to constant stimulation nor to constant blocking. The terms 'energising' or 'appetite suppressant' are therefore too simplistic for a rigorous lexicon.

Research on metabolism and appetite regulation remains exploratory. A recipe containing THCV must be described by its actual composition, without any promise of weight or blood-sugar control.

Full name. Cannabigerovarinic acid and cannabigerovarin.

Origin. Propyl-chain cannabinoids belonging to the CBG family.

CBGVA takes part in a parallel biosynthetic pathway that can lead to other 'varin'-type cannabinoids. CBGV is generally detected only in trace amounts. Available data are mainly analytical and preclinical; no reliable effect profile in humans can be claimed.

Full name. Cannabichromevarinic acid and cannabichromevarin.

Origin. Propyl homologues of CBCA and CBC.

CBCVA can decarboxylate into CBCV. These molecules illustrate the plant's natural diversity but remain poorly documented. Their presence can enrich the description of a cannabinoid spectrum; it does not allow a particular sensation or outcome to be predicted.

Full name. Cannabidiphorol and tetrahydrocannabiphorol.

Origin. Heptyl-chain phytocannabinoids identified in cannabis in trace amounts.

CBDP and THCP were characterised in 2019. THCP shows a strong affinity for CB1 in in-vitro assays and produced cannabinoid-type effects in mice. These results do not make it possible to establish a 'potency' ratio in humans. Claims such as 'three times' or 'thirty times more potent' confuse receptor affinity with real-world experience.

Natural presence in trace amounts does not describe the origin of commercial quantities, which can be obtained by transformation or synthesis. THCP is classified as a narcotic in France; it is neither recommended nor selected by Moonlight.

Full name. Cannabidihexol and tetrahydrocannabihexol.

Origin. Hexyl-chain homologues identified in very small amounts.

CBDH and THCH were described in analytical work published in 2020. Available data do not allow their effects in humans to be precisely characterised. As with THCP, a molecule identified in the plant can be produced commercially through another route; its origin must be documented batch by batch.

Full name. Tetrahydrocannabutol.

Origin. Butyl homologue of THC, identified in trace amounts.

THCB belongs to a rare natural family, but commercial products may come from chemical transformations. Human data are insufficient, and commercial claims based on an announced potency are not substantiated. Its status must be checked against the French list of narcotics and the general chemical definitions that accompany it.

Full name. Cannabicyclol and cannabicyclolic acid.

Origin. Photochemical transformation products of CBC and CBCA.

CBL and CBLA can appear when compounds of the CBC family are exposed to light. They are not known to cause THC-type intoxication. The pharmacological literature is too limited to attribute a particular effect to them.

Full name. Cannabielsoin and related compounds.

Origin. Family of oxidation products or metabolites associated with CBD.

The term CBE covers several forms and requires precise nomenclature. These compounds are studied mainly to understand the transformation and metabolism of cannabinoids. The available cellular results do not allow any clinical usefulness to be concluded.

Full name. Cannabitriol and cannabicitran.

Origin. Rare cannabinoids and families of transformation products.

The abbreviation CBT can refer to several compounds of the cannabitriol family; a full structure is therefore preferable to the acronym alone. CBTC, or cannabicitran, is another rare compound identified in cannabis. Their low abundance and the lack of human data call for a descriptive presentation, with no effect profile claimed.

The analytical literature describes other cannabinoids and homologues, including certain forms of delta-6a,10a-THC, cis forms of THCA, or chain-length variants. Their identification enriches knowledge of the plant, but does not mean they are available as standardised ingredients or that they have a documented effect in humans.